Ultralow-Power W-Band Low-Noise Amplifier Design in 130-nm SiGe BiCMOS

This paper presents a power consumption reduction aspect for a 100-GHz low-noise amplifier. Two designs implemented in 0.13-µm SiGe BiCMOS technology demonstrate state-of-the-art performance, whereas $P_{\mathrm{DC}}$ is reduced from 23.5 mW for the standard version to 3.8 mW for the low-power version. Two circuits exhibit a measured gain of 22 dB and 16 dB and a noise figure of 4 dB and 6.3 dB at 100 GHz. An input 1-dB compression point for the standard and the low-power version is -24.5 dBm and -26.5 dBm, respectively. The occupied IC area in both cases is 0.018 mm$^2$ and 0.014 mm$^2$ excluding the pads, which proves to be the most compact design among previously reported in the frequency range of interest

Ultralow-Power W-Band Low-Noise Amplifier Design in 130-nm SiGe BiCMOS

This paper presents a power consumption reduction aspect for a 100-GHz low-noise amplifier. Two designs implemented in 0.13-µm SiGe BiCMOS technology demonstrate state-of-the-art performance, whereas $P_{\mathrm{DC}}$ is reduced from 23.5 mW for the standard version to 3.8 mW for the low-power version. Two circuits exhibit a measured gain of 22 dB and 16 dB and a noise figure of 4 dB and 6.3 dB at 100 GHz. An input 1-dB compression point for the standard and the low-power version is -24.5 dBm and -26.5 dBm, respectively. The occupied IC area in both cases is 0.018 mm$^2$ and 0.014 mm$^2$ excluding the pads, which proves to be the most compact design among previously reported in the frequency range of interest

A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey

This multi-center point prevalence study evaluated children who were diagnosed as having coronavirus disease 2019 (COVID-19). On February 2nd, 2022, inpatients and outpatients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included in the study from 12 cities and 24 centers in Turkey. Of 8605 patients on February 2nd, 2022, in participating centers, 706 (8.2%) had COVID-19. The median age of the 706 patients was 92.50 months, 53.4% were female, and 76.7% were inpatients. The three most common symptoms of the patients with COVID-19 were fever (56.6%), cough (41.3%), and fatigue (27.5%). The three most common underlying chronic diseases (UCDs) were asthma (3.4%), neurologic disorders (3.3%), and obesity (2.6%). The SARS-CoV-2-related pneumoniae rate was 10.7%. The COVID-19 vaccination rate was 12.5% in all patients. Among patients aged over 12 years with access to the vaccine given by the Republic of Turkey Ministry of Health, the vaccination rate was 38.7%. Patients with UCDs presented with dyspnea and pneumoniae more frequently than those without UCDs (p < 0.001 for both). The rates of fever, diarrhea, and pneumoniae were higher in patients without COVID-19 vaccinations (p = 0.001, p = 0.012, and p = 0.027). Conclusion: To lessen the effects of the disease, all eligible children should receive the COVID-19 vaccine. The illness may specifically endanger children with UCDs. What is Known: • Children with COVID-19 mainly present with fever and cough, as in adults. • COVID-19 may specifically threaten children with underlying chronic diseases. What is New: • Children with obesity have a higher vaccination rate against COVID-19 than children without obesity. • Among unvaccinated children, fever and pneumoniae might be seen at a higher ratio than among vaccinated children